Professor of Pediatrics, Case West Res Univ
Pediatric Pulmonology
Dr. Michael W. Konstan, MD
|
|
Give Review
Michael Konstan practices Pediatric Pulmonology. He researched medicine at Case Western Reserve University School of Medicine. He over the years received 2 awards: "America's Top Doctors" and "Northern Ohio Live". Doctor Michael W. Konstan, MD is a published doctor. He published 99 publications, including: 'Transfer of the human Alpha1-antitrypsin gene into pulmonary macrophages in vivo.'
Publications
- Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in Cystic fibrosis.
- Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in Cystic fibrosis patients.
- Treatment and demographic factors affecting time to next pulmonary exacerbation in Cystic fibrosis.
- Efficacy response in CF patients treated with ivacaftor: Post-hoc analysis.
- Inflammation in Cystic fibrosis lung disease: Pathogenesis and therapy.
- Association between the introduction of a new Cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
- Pulmonary function outcomes for assessing Cystic fibrosis care.
- Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site.
- Safety, Tolerability, and Plasma Exposure of Tiotropium Respimat(®) in Children and Adults with Cystic Fibrosis.
- Pooled analysis of tiotropium Respimat(®) pharmacokinetics in Cystic fibrosis.
- A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with Cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomise...
- Liver Involvement in the Hispanic Cystic Fibrosis Population of North America.
- Ataluren for the treatment of nonsense-mutation Cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
- Early childhood wheezing is associated with lower lung function in Cystic fibrosis.
- Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
- Anti-PcrV antibody in Cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection.
- Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in Cystic fibrosis.
- Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with Cystic fibrosis.
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in Cystic fibrosis.
- Pulmonary exacerbations in Cystic fibrosis: young children with characteristic signs and symptoms.
- Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in Cystic fibrosis.
- Antibiotic and Anti-Inflammatory Therapies for Cystic Fibrosis.
- Long-term effects of pregnancy and motherhood on disease outcomes of women with Cystic fibrosis.
- Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function.
- Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with Cystic fibrosis.
- Treatment complexity in Cystic fibrosis: Trends over time and associations with site-specific outcomes.
- Changing thresholds and incidence of antibiotic treatment of Cystic fibrosis pulmonary exacerbations, 1995-2005.
- Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample.
- Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of Cystic fibrosis.
- Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample.
- A multi-center controlled trial of growth hormone treatment in children with Cystic fibrosis.
- Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with Cystic fibrosis homozygous for the F508del-CFTR mutation.
- Location and duration of treatment of Cystic fibrosis respiratory exacerbations.
- Implementation of the first worldwide quality assurance program for Cystic fibrosis multiple mutation detection in population-based screening.
- Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of Cystic fibrosis patients in Cleveland, Ohio.
- Pulmonary outcome prediction (POP) tools for Cystic fibrosis patients.
- Effect of VX-770 in persons with Cystic fibrosis and the G551D-CFTR mutation.
- Tobramycin inhalation powder for P. aeruginosa infection in Cystic fibrosis: The EVOLVE trial.
- An international randomized multicenter comparison of nasal potential difference techniques.
- Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in Cystic fibrosis.
- A pipeline of therapies for Cystic fibrosis.
- Anti-inflammatory therapies for Cystic fibrosis-related lung disease.
- Ibuprofen therapy for Cystic fibrosis lung disease: revisited.
- Clinical use of Ibuprofen is associated with slower FEV1 decline in children with Cystic fibrosis.
- Sputum biomarkers of inflammation in Cystic fibrosis lung disease.
- Duration of treatment effect after tobramycin solution for inhalation in young children with Cystic fibrosis.
- Inflammation and anti-inflammatory therapies for Cystic fibrosis.
- Association between pulmonary function and sputum biomarkers in Cystic fibrosis.
- Novel tobramycin inhalation powder in Cystic fibrosis subjects: pharmacokinetics and safety.
- Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with Cystic fibrosis.
- Classifying severity of Cystic fibrosis lung disease using longitudinal pulmonary function data.
- Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient Cystic fibrosis patients.
- Impact of pregnancy on women with Cystic fibrosis.
- The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with Cystic fibrosis.
- Beta 2 adrenergic receptor polymorphisms in Cystic fibrosis.
- Anti-inflammatory medications for Cystic fibrosis lung disease: selecting the most appropriate agent.
- Compacted DNA nanoparticles administered to the nasal mucosa of Cystic fibrosis subjects are safe and demonstrate partial to complete Cystic fibrosis transmembrane reg...
- Relation of sweat chloride concentration to severity of lung disease in Cystic fibrosis.
- Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter Cystic fibrosis clinical trials.
- Effect of ibuprofen on neutrophil migration in vivo in Cystic fibrosis and healthy subjects.
- Factors influencing outcomes in Cystic fibrosis: a center-based analysis.
- The role of inflammation in the pathophysiology of CF lung disease.
- Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice.
- A phase I randomized, multicenter trial of CPX in adult subjects with mild Cystic fibrosis.
- Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with Cystic fibrosis.
- Inflammatory mediators in CF patients.
- Murine models of CF airway infection and inflammation.
- Normalized T1 Magnetic Resonance Imaging for Assessment of Regional Lung Function in Adult Cystic Fibrosis Patients - A Cross-Sectional Study.
- Transfer of the human Alpha1-antitrypsin gene into pulmonary macrophages in vivo.
- Design and powering of Cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.
- Design and powering of Cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.
- Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in Cystic fibrosis: safety and efficacy.
- Effect of smaller droplet size of dornase alfa on lung function in mild Cystic fibrosis. Dornase Alfa Nebulizer Group.
- Excessive inflammatory response of Cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.
- Treatment of airway inflammation in Cystic fibrosis.
- Current understanding of the inflammatory process in Cystic fibrosis: onset and etiology.
- Identifying treatments that halt progression of pulmonary disease in Cystic fibrosis.
- Inflammatory cytokines in Cystic fibrosis lungs.
- Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with Cystic fibrosis.
- Efficacy of the Flutter device for airway mucus clearance in patients with Cystic fibrosis.
- Tissue-specific Fc gamma and complement receptor expression by alveolar macrophages determines relative importance of IgG and complement in promoting phagocytosis of P...
- Bronchoalveolar lavage findings in Cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.
- Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in Cystic fibrosis indicate absence of antibody-mediated protectio...
- Elastin and collagen degradation products in urine of patients with Cystic fibrosis.
- Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in Cystic fibrosis.
- Effect of high-dose ibuprofen in patients with Cystic fibrosis.
- Acute loxapine intoxication in a child.
- A comparative study of lysozyme and its secretion by tracheal epithelium.
- Pseudomonas cepacia-associated pneumonia in Cystic fibrosis. Relation of clinical features to histopathologic patterns of pneumonia.
- The pathologic characteristics of interstitial pneumonia Cystic fibrosis. A retrospective autopsy study.
- Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cy...
- Ibuprofen in children with Cystic fibrosis: pharmacokinetics and adverse effects.
- A two-year randomized, placebo-controlled trial of dornase alfa in young patients with Cystic fibrosis with mild lung function abnormalities.
- Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with Cystic fibrosis.
- Safety of aerosolized INS 365 in patients with mild to moderate Cystic fibrosis: results of a phase I multi-center study.
- Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice.
- IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice.
- Patterns of medical practice in Cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
Schools
Case Western Reserve University School of Medicine
Chldns Hospital
Rainbow Babies Chldns Hospital
Conditions Treated
- Cystic Fibrosis
- Pneumonia
Doctors Specialties
- Pediatric Pulmonology
Accepted Insurances
Awards
- America's Top Doctors
- Northern Ohio Live
Education
-
Case Western Reserve University - University Hospitals -
Case Western Reserve University School of Medicine
Hospital
-
University Hospitals Case Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Samuel A. Fagenholz, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Laura J. Milgram, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Meeghan A. Hart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Carl, MD |
|
Dr. Daniel I. Craven, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Birnkrant, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tracy L. Ivy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pooja Puri, MD |
|
|
Dr. Catherine E. Walker, MD
This Doctor is OpenDoctor Recommended.
|